Last reviewed · How we verify
anti-VEGF agent
Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis.
Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | anti-VEGF agent |
|---|---|
| Also known as | Cohort 1 - Quantitative, Cohort 2 - Qualitative |
| Sponsor | Medical University of Vienna |
| Drug class | Anti-angiogenic agent (VEGF inhibitor) |
| Target | VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology, Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
VEGF is a key driver of neovascularization in tumors and certain ocular diseases. By neutralizing VEGF or its receptors, anti-VEGF agents starve tumors of blood supply and reduce pathological vessel growth. This class includes monoclonal antibodies (e.g., bevacizumab), receptor tyrosine kinase inhibitors, and other biologics targeting the VEGF pathway.
Approved indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Metastatic breast cancer
- Renal cell carcinoma
- Wet age-related macular degeneration
- Diabetic retinopathy
Common side effects
- Hypertension
- Proteinuria
- Bleeding
- Thrombotic events
- Wound healing complications
- Gastrointestinal perforation
- Fatigue
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-VEGF agent CI brief — competitive landscape report
- anti-VEGF agent updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI